SBC003 demonstrates neuroprotective effects in a murine model of N-nitroso-N-methylurea (NMU) induced photoreceptor degeneration. DONG Y et al. Invest. Ophthalmol. Vis. Sci. 2020;61(7):2475. Abstract
The uni-nephrectomized and salt-loaded SDT fatty rat, a novel type 2 diabetic model of diabetic nephropathy, develops features of diabetic retinopathy. SHINOHARA M et al. Japanese Society of Toxicologic Pathology meeting 2020; Tokuo, JAPAN
The uni-nephrectomized SDT fatty rat, a novel type 2 diabetic model of diabetic nephropathy, develops features of diabetic retinopathy over 10 weeks. BRIAND F et al. ARVO meeting 2018; Hawaii - USA. Invest. Ophthalmol. Vis. Sci. 2018; 59(9):3573. doi: Poster| Abstract
Conditional self-knockout of otx2 mice: a new model for late-onset neuronal degeneration. ELENA PP et al. ARVO meeting 2017; Baltimore - USA. Invest. Ophthalmol. Vis. Sci. 2017; 58(8):4532. doi:Abstract
Norbixin protects retinal pigmented epithelium cells and photoreceptors against A2E-mediated phototoxicity in vitro and in vivo. FONTAINE V et al. PLOS ONE 11(12): e0167793. doi:10.1371/journal.pone.0167793Article
BIO201: a new drug candidate for the treatment of dry AMD. FONTAINE V et al. ARVO meeting 2016; Seattle - USA. Invest. Ophthalmol. Vis. Sci. 2016; 57(12):1119. doi: Poster
Protection of blue light induced retinal degeneration by the free radical scavenger Phenyl-N-tert-butylnitrone and a serotonin receptor 5-HT1a agonist in rats. GRILLO-ANTONELLI S et al. EVER meeting 2012; Nice - France. Poster S063 Poster| Abstract
Multiple topical administrations of Ramipril enhance retinal ganglion cell survival after transient retinal ischemia-reperfusion in rats. ELENA PP et al. EVER meeting 2012; Nice - France. Poster F029 Abstract
Protective effect of nicardipine, a calcium channel blocker on electroretinogram and retinal cytoskeletal damages after ischemia-reperfusion on the rat. FREDJ-REYGROBELLET D et al. ARVO meeting 1998; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1998; 39:S993
Retinal damage and protection after ischemic injury in the rat: a reappraisal. ELENA PP et al. ARVO meeting 1997; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1997; 38:S888
Protection induced by isopropyl unoprostone treatment after retinal ischemic injury in the rat. MOREL MANDRINO P and al. ARVO meeting 1997; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1997; 38:S103
Histological and cytological retinal changes after pressure-induced ischemia in rat eye. FREDJ-REYGROBELLET D et al. Vision Res. 1996;36:S220
«My drug candidate or medical device shows promise in treating ocular diseases. Help me to achieve high added value»
With Iris Pharma by your side you will
Demonstrate your product’s value
Bridge the gap between innovation and pharmaceutical products
Capture investors’ and venture capitalists’ attention to secure development funding
Prepare your product for the licensing process
Start a collaboration with a partner
« I need a full preclinical package or clinical trials for my ocular drug or ophthalmic medical »
While working with Iris Pharma you will
Master requirements: regulatory requirements, the right data to assemble and key studies
Master the steps, milestones and deadlines
« I’d like to assess the possible therapeutic value of my lead compound in ocular diseases »
Entrust Iris Pharma to
Get valuable information from cost effective studies to guide your future work
Quickly and easily determine the efficacy, PK and safety profiles of your compounds
View trends before moving forward
« I need a step-by-step approach and “À la carte” studies »
Contract with Iris Pharma to
Immediately benefit from the unique know-how and resources of a renowned expert in ophthalmology able to understand your needs and intervene at any stage of your program
